These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 15836919

  • 1. Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.
    Chen J, Lee CT, Errico S, Deng X, Cadet JL, Freed WJ.
    Brain Res Mol Brain Res; 2005 Apr 04; 134(2):215-25. PubMed ID: 15836919
    [Abstract] [Full Text] [Related]

  • 2. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity.
    Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA.
    Mol Pharmacol; 2006 Mar 04; 69(3):691-6. PubMed ID: 16299067
    [Abstract] [Full Text] [Related]

  • 3. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
    Liu Q, Bhat M, Bowen WD, Cheng J.
    J Pharmacol Exp Ther; 2009 Dec 04; 331(3):1062-70. PubMed ID: 19752241
    [Abstract] [Full Text] [Related]

  • 4. Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
    Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP.
    Neuropathol Appl Neurobiol; 2012 Oct 04; 38(6):535-47. PubMed ID: 22236282
    [Abstract] [Full Text] [Related]

  • 5. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
    Araya KA, David Pessoa Mahana C, González LG.
    Eur J Pharmacol; 2007 Oct 15; 572(1):32-9. PubMed ID: 17644088
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Delta 9-tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed.
    Wilkinson JD, Kendall DA, Ralevic V.
    Br J Pharmacol; 2007 Nov 15; 152(5):709-16. PubMed ID: 17828286
    [Abstract] [Full Text] [Related]

  • 9. Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.
    De Vry J, Jentzsch KR.
    Behav Pharmacol; 2004 Feb 15; 15(1):13-20. PubMed ID: 15075622
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
    Wiley JL, Lowe JA, Balster RL, Martin BR.
    J Pharmacol Exp Ther; 1995 Oct 15; 275(1):1-6. PubMed ID: 7562536
    [Abstract] [Full Text] [Related]

  • 12. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.
    Järbe TU, LeMay BJ, Halikhedkar A, Wood J, Vadivel SK, Zvonok A, Makriyannis A.
    Psychopharmacology (Berl); 2014 Feb 15; 231(3):489-500. PubMed ID: 24005529
    [Abstract] [Full Text] [Related]

  • 13. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity.
    Gilbert GL, Kim HJ, Waataja JJ, Thayer SA.
    Brain Res; 2007 Jan 12; 1128(1):61-9. PubMed ID: 17140550
    [Abstract] [Full Text] [Related]

  • 14. Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression.
    Pozzoli G, Tringali G, Vairano M, D'Amico M, Navarra P, Martire M.
    J Neurosci Res; 2006 May 01; 83(6):1058-65. PubMed ID: 16609959
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR.
    J Pharmacol Exp Ther; 2006 Dec 01; 319(3):1211-8. PubMed ID: 16943255
    [Abstract] [Full Text] [Related]

  • 17. Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats.
    del Carmen García M, Adler-Graschinsky E, Celuch SM.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Oct 01; 368(4):270-6. PubMed ID: 14504685
    [Abstract] [Full Text] [Related]

  • 18. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
    Darmani NA, Chebolu S, Zhong W, Trinh C, McClanahan B, Brar RS.
    Eur J Pharmacol; 2014 Jan 05; 722():147-55. PubMed ID: 24157976
    [Abstract] [Full Text] [Related]

  • 19. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
    Darmani NA, Janoyan JJ, Crim J, Ramirez J.
    Eur J Pharmacol; 2007 Jun 01; 563(1-3):187-96. PubMed ID: 17362921
    [Abstract] [Full Text] [Related]

  • 20. Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action.
    Köfalvi A, Vizi ES, Ledent C, Sperlágh B.
    Eur J Neurosci; 2003 Oct 01; 18(7):1973-8. PubMed ID: 14622229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.